AZD8233 reduced low-density lipoprotein cholesterol levels by 73%

AstraZeneca (LSE: AZN) has announced Phase IIb results from the ETESIAN trial that showed AZD8233 reached a statistically-significant and clinically-meaningful reduction (of 73% change) from baseline in low-density lipoprotein cholesterol (LDL-C) levels.

The Anglo-Swedish pharm major is developing the compound under a collaboration with California, USA-based Ionis Pharmaceuticals (Nasdaq: IONIS).

The trial also met the secondary endpoints, including significantly reducing proprotein convertase subtilisin/kexin type 9 (PCSK9) levels by 89% (95% CI: -91%, -86%), with sustained reductions maintained over the dosing intervals, and through to week 14 (6 weeks after last dose) at 50 mg dose. Reduction of PCSK9 levels leads to increases in LDL receptor levels, which results in lower LDL-C levels in the bloodstream and reduces the risk of developing coronary heart disease. AZD8233 was generally well-tolerated during the treatment duration.